SQNM.F Stock Overview

Develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. More details

SQNM.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Revenue is forecast to grow 101.57% per year

Risk Analysis

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Makes less than USD$1m in revenue (€434K)

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Sequana Medical NV Competitors

Outset Medical

NasdaqGS:OM

US$53.6m

Baird Medical Investment Holdings

NasdaqCM:BDMD

US$55.5m

Medinotec

OTCPK:MDNC

US$58.7m

enVVeno Medical

NasdaqCM:NVNO

US$45.1m

Price History & Performance

Summary of share price highs, lows and changes for Sequana Medical
Historical stock prices
Current Share Price	€0.78
52 Week High	€3.00
52 Week Low	€0.78
Beta	0.88
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-74.00%

Recent updates

Shareholder Returns

	SQNM.F	US Medical Equipment	US Market
7D	n/a	-3.4%	-3.5%
1Y	n/a	9.0%	22.1%

Return vs Industry: Insufficient data to determine how SQNM.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how SQNM.F performed against the US Market.

Price Volatility

Is SQNM.F's price volatile compared to industry and market?
SQNM.F volatility
SQNM.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	7.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: SQNM.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SQNM.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	62	Ian Crosbie	www.sequanamedical.com

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, Switzerland, and internationally. The company products pipeline comprises alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body and heart failure. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.

Sequana Medical NV Fundamentals Summary

How do Sequana Medical's earnings and revenue compare to its market cap?
SQNM.F fundamental statistics
Market cap	US$32.16m
Earnings (TTM)	-US$28.18m
Revenue (TTM)	US$449.46k

71.5x

P/S Ratio

-1.1x

P/E Ratio

Is SQNM.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SQNM.F income statement (TTM)
Revenue	€433.50k
Cost of Revenue	€101.74k
Gross Profit	€331.76k
Other Expenses	€27.51m
Earnings	-€27.18m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.61
Gross Margin	76.53%
Net Profit Margin	-6,269.81%
Debt/Equity Ratio	-111.3%

How did SQNM.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 04:24
End of Day Share Price	2024/12/18 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sequana Medical NV is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Laura Roba	Degroof Petercam
Yi Chen	H.C. Wainwright & Co.
Thomas Vranken	KBC Securities NV